棕榈酰化
病毒复制
复制子
生物
病毒学
蓝蛋白
复制(统计)
冠状病毒
脂滴
病毒
细胞生物学
遗传学
脂质代谢
2019年冠状病毒病(COVID-19)
生物化学
医学
基因
传染病(医学专业)
酶
基因组
疾病
脂肪酸合酶
半胱氨酸
病理
作者
Dongxiao Liu,Ruth Cruz‐Cosme,Julian L. Leibowitz,Yong Wu,Qiyi Tang
出处
期刊:
[Cold Spring Harbor Laboratory]
日期:2023-06-30
被引量:1
标识
DOI:10.1101/2023.06.29.547086
摘要
ABSTRACT The emergence of viral infections with global impact highlights the urgent need for broad-spectrum antivirals. In this study, we evaluated the effect of palmitoylation inhibitors [2-bromopalmitate (2-BP), cerulenin, and 2-fluoro palmitic acid (2-FPA)] and the enhancer palmostatin B on the replication of human coronaviruses (hCoV-229E, hCoV-Oc43) and murine hepatitis virus (MHV-A59) at non-cytotoxic concentrations. The results demonstrated that 2-BP strongly suppressed MHV-A59 replication, while cerulenin and 2-FPA only moderately inhibited viral replication. Palmostatin B significantly enhanced viral replication. Notably, 2-BP exhibited superior efficacy. Interestingly, palmostatin B failed to rescue the inhibitory effects of 2-BP but effectively rescued cerulenin and 2-FPA, suggesting additional biological activities of 2-BP beyond palmitoylation inhibition. Furthermore, we discovered that 2-BP specifically disrupted lipid droplets (LDs), and this LD disruption was correlated with viral replication inhibition. Based on our findings, we conclude that the inhibitory effects of 2-BP on viral replication primarily stem from LD disruption rather than palmitoylation inhibition. Therefore, we revealed the crucial role of LDs in the viral replication. Our study provides insights into the development of wide-spectrum antiviral strategies.
科研通智能强力驱动
Strongly Powered by AbleSci AI